Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06632379 · ClinicalTrials.gov registry record · Phase 4
AtorvaStatin Postpartum and Reduction of Cardiovascular risK
A Phase 4 study of Preeclampsia and Gestational Hypertension, sponsored by Ohio State University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT06632379 is a Phase 4 study of Preeclampsia and Gestational Hypertension that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 76 participants, below the 1,280-participant average among 39 other Preeclampsia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06632379, a Phase 4 study of Preeclampsia and Gestational Hypertension, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atorvastatin 10 mg
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06632379
The ClinicalTrials.gov registry entry for NCT06632379 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,280-participant average among 39 other Preeclampsia trials with a reported enrollment target (94% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06632379 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06632379 about?
NCT06632379 is a clinical study titled "AtorvaStatin Postpartum and Reduction of Cardiovascular risK". The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be...
What is the current status of trial NCT06632379?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2025-10-03. Estimated completion is 2026-12-15.
What conditions does trial NCT06632379 study?
This clinical trial studies the following conditions: Preeclampsia, Gestational Hypertension, Hypertensive Disorders of Pregnancy.
What interventions are being tested in trial NCT06632379?
The interventions under investigation include: Placebo (DRUG), Atorvastatin 10 mg (DRUG).
Who is sponsoring clinical trial NCT06632379?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06632379 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
RECRUITING · Phase 4
-
Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
ACTIVE NOT RECRUITING · Phase 4
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.